Fox Run Management L.L.C. Grows Holdings in Bristol Myers Squibb Company $BMY

Fox Run Management L.L.C. grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 60.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,032 shares of the biopharmaceutical company’s stock after buying an additional 15,894 shares during the period. Bristol Myers Squibb makes up about 0.3% of Fox Run Management L.L.C.’s holdings, making the stock its 20th biggest holding. Fox Run Management L.L.C.’s holdings in Bristol Myers Squibb were worth $2,267,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Norges Bank purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $1,947,272,000. Bank of New York Mellon Corp grew its stake in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after buying an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC grew its stake in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after buying an additional 6,084,046 shares in the last quarter. Man Group plc grew its stake in Bristol Myers Squibb by 280.4% in the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after buying an additional 5,503,391 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of Bristol Myers Squibb by 530.6% in the 3rd quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock valued at $245,946,000 after purchasing an additional 4,588,601 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Down 2.9%

NYSE:BMY opened at $55.64 on Tuesday. The company has a fifty day moving average of $58.02 and a 200 day moving average of $56.65. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The firm has a market capitalization of $113.61 billion, a P/E ratio of 15.63, a P/E/G ratio of 0.16 and a beta of 0.24.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same period in the prior year, the business posted $1.80 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Wall Street Analyst Weigh In

BMY has been the subject of a number of research reports. Bank of America cut their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, April 9th. Royal Bank Of Canada initiated coverage on shares of Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective for the company. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a research note on Friday, May 1st. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Barclays initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 price objective for the company. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.